Neurotransmitter depleter tetrabenazine; potential candidate for schizophrenia treatment?

  title={Neurotransmitter depleter tetrabenazine; potential candidate for schizophrenia treatment?},
  author={Abid Malik and Victoria I. Balkoski},
  journal={Schizophrenia Research},

Efficacy of Vesicular Monoamine Transporter 2 Inhibition and Synergy with Antipsychotics in Animal Models of Schizophrenia

Combining these postsynaptic dopaminergic modulators with a presynaptic dopamine modulator potentiates efficacy synergistically in animal models of schizophrenia without potentiating weight gain.

The role of cognitive control in memory retrievalapplications to schizotypy and schizophrenia

These experiments examined whether differences in target and non-target left-parietal old/new effects – a proposed neural correlate of strategic control over recollection - are predicted by schizotypy and/or schizophrenia symptomology.

Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders.

  • D. Guay
  • Medicine, Psychology
    The American journal of geriatric pharmacotherapy
  • 2010



Neuroleptic Malignant syndrome caused by dopamine‐depleting drugs in a patient with Huntington disease

The occurrence of NMS caused by dopamine-depleting agents suggests that anticholinergic properties of phenotiazines are not the only cause, and central dopaminergic systems probably participate in thermo-regulation, and dopamine depletion probably plays a pathogenetic role in this syndrome.

A comparison of tetrabenazine and chlorpromazine in chronic schizophrenia.

Although side-effects caused suspension of treatment in five patients in the tetrabenazine group, the drug may be safely administered to patients in hospital and appears to be worthy of more extensive trial.

The cost of schizophrenia: lessons from an international comparison.

A key finding in the paper is the very large difference in the per capita cost of treatment of schizophrenia in Canada and the United States.

Pharmacological management of Huntington's disease: an evidence-based review.

There is poor evidence in management of HD today and the analysis of the twenty level-I studies fails to result in any treatment recommendation of clinical relevance, so high-quality RCT are highly warranted to advance HD treatment in clinical practice.

Treatment with the new antipsychotic sertindole for late-occurring undesirable movement effects.

  • L. Perquin
  • Psychology, Medicine
    International clinical psychopharmacology
  • 2005
The beneficial effect of sertindole on severe, late-occurring movement disorders, as observed in four difficult-to-treat patients, appears to be promising.

Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.

For patients with schizophrenia who prospectively failed to improve with an atypical antipsychotic, clozapine was more effective than switching to another newer atypicals antipsychotics.

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

Olanzapine was the most effective in terms of the rates of discontinuation, and the efficacy of the conventional antipsychotic agent perphenazine appeared similar to that of quetiapine, risperidone, and ziprasidone.

Cost of schizophrenia in England.

  • R. MangaloreM. Knapp
  • Medicine, Political Science
    The journal of mental health policy and economics
  • 2007
Schizophrenia continues to be a high cost illness because of the range of health needs that people have and decision-makers need to recognise the breadth of economic impacts, well beyond the health system as conventionally defined.